INCY

Incyte (INCY)

Incyte Corporation

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:NASDAQ:INCY

1 2 3 4 5 6 7 8 9 10 다음 >>

일자	시간	출처	헤드라인	심볼	기업
2024/09/19	06:15	PR Newswire (US)	Incyte and Syndax Announce New England Journal of Medicine Publication of Data from Pivotal AGAVE-201 Trial of Niktimvo™ (axatilimab-csfr) in Chronic Graft-Versus-Host Disease	NASDAQ:INCY	Incyte Corporation
2024/09/17	02:25	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:INCY	Incyte Corporation
2024/09/17	02:24	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:INCY	Incyte Corporation
2024/09/16	07:36	Business Wire	Retifanlimab (Zynyz®) von Incyte verlängert progressionsfreies Überleben bei Patienten mit Plattenepithel-Analkarzinom (SCAC) – Datenpräsentation beim ESMO Presidential Symposium 2024	NASDAQ:INCY	Incyte Corporation
2024/09/15	14:34	Business Wire	INCB123667, l'inhibiteur de la CDK2 d'Incyte, montre des signes prometteurs d'activité clinique chez des patientes atteintes de tumeurs solides avancées, notamment le cancer de l'ovaire	NASDAQ:INCY	Incyte Corporation
2024/09/15	14:34	Business Wire	Incyte’s CDK2 Inhibitor INCB123667 zeigt vielversprechende Anzeichen von klinischer Wirkung bei Patienten mit soliden Tumoren in fortgeschrittenem Stadium	NASDAQ:INCY	Incyte Corporation
2024/09/15	13:48	Business Wire	Le rétifanlimab (Zynyz®) d’Incyte prolonge la survie sans progression chez les patients atteints de carcinome épidermoïde du canal anal (SCAC) ; des données ont été présentées lors du Symposium présidentiel de l’ESMO 2024	NASDAQ:INCY	Incyte Corporation
2024/09/15	01:45	Business Wire	Incyte’s CDK2 Inhibitor INCB123667 Shows Promising Evidence of Clinical Activity in Patients with Advanced Solid Tumors, Notably Ovarian Cancer	NASDAQ:INCY	Incyte Corporation
2024/09/14	23:30	Business Wire	Incyte’s Retifanlimab (Zynyz®) Extends Progression-Free Survival in Patients with Squamous Cell Anal Carcinoma (SCAC); Data Featured at ESMO 2024 Presidential Symposium	NASDAQ:INCY	Incyte Corporation
2024/09/14	05:06	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:INCY	Incyte Corporation
2024/09/13	05:17	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:INCY	Incyte Corporation
2024/09/10	05:30	Business Wire	Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	NASDAQ:INCY	Incyte Corporation
2024/08/22	05:49	Business Wire	Incyte präsentiert bahnbrechende Phase 3-Ergebnisse für Retifanlimab (Zynyz®) und erste Daten aus Phase 1 des CDK2-Inhibitor-Programms auf dem Kongress der European Society of Medical Oncology (ESMO) 2024	NASDAQ:INCY	Incyte Corporation
2024/08/22	05:49	Business Wire	Incyte présentera les résultats de la phase 3 de Retifanlimab (Zynyz®) et les données initiales du programme d'inhibiteurs de CDK2 de phase 1 à l'édition 2024 du Congrès de la Société européenne d'oncologie médicale (ESMO)	NASDAQ:INCY	Incyte Corporation
2024/08/22	00:40	Business Wire	Incyte to Present Late-Breaking Phase 3 Results for Retifanlimab (Zynyz®) and Initial Data from Phase 1 CDK2 Inhibitor Program at the European Society of Medical Oncology (ESMO) Congress 2024	NASDAQ:INCY	Incyte Corporation
2024/08/16	18:59	Business Wire	Incyte gibt positive Topline-Ergebnisse der Pivotalstudie mit Tafasitamab (Monjuvi®) bei rezidiviertem oder refraktärem follikulärem Lymphom bekannt	NASDAQ:INCY	Incyte Corporation
2024/08/16	18:46	Business Wire	Incyte annonce des résultats positifs de l'étude pivot sur le tafasitamab (Monjuvi®) dans le lymphome folliculaire récidivant ou réfractaire	NASDAQ:INCY	Incyte Corporation
2024/08/16	05:30	Business Wire	Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®) in Relapsed or Refractory Follicular Lymphoma	NASDAQ:INCY	Incyte Corporation
2024/08/16	05:15	Business Wire	Incyte und Syndax melden FDA-Zulassung von Niktimvo™ (Axatilimab-csfr) zur Behandlung der chronischen Graft-versus-Host-Krankheit (GvHD)	NASDAQ:INCY	Incyte Corporation
2024/08/15	19:26	Business Wire	Incyte et Syndax annoncent l’approbation par la FDA américaine de Niktimvo™ (axatilimab-csfr) pour le traitement de la maladie chronique du greffon contre l’hôte (GVHD)	NASDAQ:INCY	Incyte Corporation
2024/08/15	06:34	Business Wire	Incyte and Syndax Announce U.S. FDA Approval of Niktimvo™ (axatilimab-csfr) for the Treatment of Chronic Graft-Versus-Host Disease (GVHD)	NASDAQ:INCY	Incyte Corporation
2024/08/15	04:37	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:INCY	Incyte Corporation
2024/08/13	21:00	Business Wire	Incyte to Present at Upcoming Investor Conferences	NASDAQ:INCY	Incyte Corporation
2024/08/13	05:39	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:INCY	Incyte Corporation
2024/08/08	06:00	Business Wire	Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	NASDAQ:INCY	Incyte Corporation
2024/07/30	20:15	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:INCY	Incyte Corporation
2024/07/30	20:00	Business Wire	Incyte Reports 2024 Second Quarter Financial Results and Provides Updates on Key Clinical Programs	NASDAQ:INCY	Incyte Corporation
2024/07/30	04:50	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:INCY	Incyte Corporation
2024/07/26	05:09	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:INCY	Incyte Corporation
2024/07/25	03:20	Edgar (US Regulatory)	Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]	NASDAQ:INCY	Incyte Corporation